Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression is a phase 1/2, interventional study registered as NCT07655622 by Second Affiliated Hospital of Nanchang University, with a registry enrolment figure of 45 participants, started 2026-07-03 and due to reach its primary completion in 2027-12-03. Interventions recorded: Vebreltinib; Furmonertinib 80mg. Conditions listed: Non-Small-Cell Lung Cancer. Primary outcome: Phase Ib: Incidence of Dose-Limiting Toxicities as assessed by protocol-defined criteria and CTCAE v5.0; Phase Ib: Incidence of Grade ≥2 Treatment-Emergent Adverse Events as assessed by CTCAE v5.0; Phase Ib: Rate of dose reduction, interruption, or discontinuation due to treatment-related adverse ev. Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced (stage IIIB-IIIC), metastatic, or recurrent (stage IV) non-small cell lung cancer, not amenable to surgical resection and definitive concurrent chemoradiotherapy". Sites: China. No results are recorded here; the registry entry is the source.